Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
- PMID: 31401742
- PMCID: PMC6942575
- DOI: 10.1007/s10554-019-01684-9
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
Abstract
The aim of this study was to determine whether left atrial ejection fraction (LAEF) quantified with cardiovascular magnetic resonance (CMR) was different between heart failure with preserved ejection fraction (HFpEF) and controls, and its relation to prognosis. As part of our single-centre, prospective, observational study, 188 subjects (HFpEF n = 140, controls n = 48) underwent phenotyping with contrast-enhanced CMR, transthoracic echocardiography, blood sampling and six-minute walk testing. LAEF was calculated using the biplane method. Atrial fibrillation (AF) was present in 43 (31%) of HFpEF subjects. Overall, LAEF (%) was lower in HFpEF patients inclusive of AF (32 ± 16) or those in sinus rhythm alone (41 ± 12) compared to controls (51 ± 11), p < 0.0001. LAEF correlated inversely with maximal and minimal left atrial volumes indexed (r = - 0.602, r = - 0.762), and plasma N-terminal pro-atrial natriuretic peptide (r = - 0.367); p < 0.0001. During median follow-up (1429 days), there were 67 composite events of all-cause death or hospitalization for heart failure (22 deaths, 45 HF hospitalizations) in HFpEF. Lower LAEF (below median) was associated with an increased risk of composite endpoints (Log-Rank: all p = 0.028; sinus p = 0.036). In multivariable Cox regression analysis, LAEF (adjusted hazard ratio [HR] 0.767, 95% confidence interval [CI] 0.591-0.996; p = 0.047) and indexed extracellular volume (HR 1.422, CI 1.015-1.992; p = 0.041) were the only parameters that remained significant when added to a base prognostic model comprising age, prior HF hospitalization, diastolic blood pressure, lung disease, NYHA, six-minute-walk-test-distance, haemoglobin, creatinine and B-type natriuretic peptide. CMR-derived LAEF is lower in HFpEF compared to healthy controls and is a strong prognostic biomarker.
Keywords: Biomarker; Cardiovascular magnetic resonance imaging; Heart failure with preserved ejection fraction; Left atrial ejection fraction; Prognosis.
Conflict of interest statement
Lei Zhao and Jing Yang are employees of Bristol Myers Squibb which facilitated plasma NTpro-ANP analysis. All other authors declare that they have no competing interests relevant to this study. All authors also state that they have full control of all primary data and that they agree to allow the journal to review their data if requested.
Figures
Comment in
-
Left atrial function and NT-proANP as markers of AF progression and impaired outcome in patients with heart failure with preserved ejection fraction.Int J Cardiovasc Imaging. 2020 Jan;36(1):121-122. doi: 10.1007/s10554-019-01701-x. Epub 2019 Oct 5. Int J Cardiovasc Imaging. 2020. PMID: 31587127 No abstract available.
References
-
- Agner BF, Kuhl JT, Linde JJ, et al. Assessment of left atrial volume and function in patients with permanent atrial fibrillation: comparison of cardiac magnetic resonance imaging, 320-slice multi-detector computed tomography, and transthoracic echocardiography. Eur Heart J Cardiovasc Imaging. 2014;15(5):532–540. doi: 10.1093/ehjci/jet239. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- RP-2017-08-ST2-007/DH_/Department of Health/United Kingdom
- CDF 2014-07-045/National Institute for Health Research
- Overall project Grant: IRS_BRU_0211_20033/National Institute for Health Research (NIHR) Leicester Cardiovascular Biomedical Research Centre
- PDF-2011-0451/National Institute for Health Research
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
